Details of the Drug Formulations

General Information of Drug (ID: DMCBJSR)

Drug Name
Sunitinib Drug Info
Synonyms
Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Acute undifferentiated leukemia Approved [1]
Chronic myelomonocytic leukemia Approved [1]
Classic Kaposi sarcoma Approved [1]
Gastrointestinal cancer 2C11 Approved [2]
Gastrointestinal stromal tumour 2B5B Approved [3]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lung cancer 2C25.0 Approved [1]
Mast cell leukaemia 2A21.00 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Pancreatic cancer 2C10 Approved [1]
Primary myelofibrosis 2A20.2 Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Prostate adenocarcinoma Approved [1]
Refractory chronic myeloid leukaemia 2A20 Approved [1]
Salivary gland squamous cell carcinoma Approved [1]
Plexiform neurofibroma Investigative [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
5329102
ChEBI ID
CHEBI:38940
CAS Number
557795-19-4
TTD ID
D0R0MW
VARIDT ID
DR00454
INTEDE ID
DR1519
ACDINA ID
D00646

Full List of Drug Formulations Containing This Drug

Sunitinib 25 mg capsule
Company Formulation ID FDA Description
Pfizer Laboratories F20569 Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Potassium hydroxide; Propylene glycol; Sodium hydroxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified; Povidone k25; Povidone, unspecified; Shellac
------------------------------------------------------------------------------------
Sunitinib 37.5 mg capsule
Company Formulation ID FDA Description
Pfizer Laboratories F20570 Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Potassium hydroxide; Propylene glycol; Sodium hydroxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified; Povidone k25; Povidone, unspecified; Shellac
------------------------------------------------------------------------------------
Sunitinib 50 mg capsule
Company Formulation ID FDA Description
Pfizer Laboratories F20571 Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Potassium hydroxide; Propylene glycol; Sodium hydroxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified; Povidone k25; Povidone, unspecified; Shellac
------------------------------------------------------------------------------------
Sunitinib 12.5 mg capsule
Company Formulation ID FDA Description
Pfizer Laboratories F20568 Magnesium stearate; Mannitol; Ferric oxide red; Potassium hydroxide; Propylene glycol; Sodium hydroxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified; Povidone k25; Povidone, unspecified; Shellac
------------------------------------------------------------------------------------

References

1 Sunitinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.